Amplia Therapeutics has used one of the world’s largest oncology stages to sharpen its case for narmafotinib, presenting mature data from its ACCENT trial that suggest the drug could meaningfully shift outcomes in one of the most difficult-to-treat cancers. …
Amplia positions narmafotinib as a potential step change in pancreatic cancer
April 22, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 24 April
April 24, 2026 - - Podcast -
Prevention warning as Pfizer urges Budget reset on vaccines and immunisation
April 24, 2026 - -
NDIS fraud is so extensive that 'prosecuting our way out of it' is now impractical
April 24, 2026 - - Latest News -
Boehringer Ingelheim and Heart of Australia take mobile lung care deeper into regional Australia
April 24, 2026 - - Latest News -
A decade to diagnosis highlights hidden burden of immune disorders
April 24, 2026 - - Latest News -
Quiet diplomacy as Australia navigates global pricing pressure, but can it work?
April 24, 2026 - - Latest News -
New immunotherapy option approved for Australians with relapsed follicular lymphoma
April 24, 2026 - - Latest News